Yttrium is a metal of the rare earth group of elements. A radioactive form of yttrium may be attached to a monoclonal antibody or other molecule that can locate and bind to cancer cells and be used to diagnose or treat some types of cancer.
Researchers at the Virginia Tech Carilion Research Institute have reported the first experimental evidence that supports the theory that a soccer ball-shaped nanoparticle commonly called a buckyball is the result of a breakdown of larger structures rather than being built atom-by-atom from the ground up.
Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.
Peptide-receptor radionuclide therapy has been a subject of growing research on neuroendocrine tumors, which take up residence in a variety of organs replete with nerve cells that respond to hormone signaling.
Researchers at Aldrich Materials Science, a strategic technology initiative of Sigma-Aldrich Corporation have discovered an innovative way to design an important class of three-dimensional (3D) hybrid structures, Metal Organic Frameworks (MOFs), under completely liquid-free conditions.
Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced new clinical data presented in an oral presentation for ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use at the 17th Congress of the European Hematology Association (EHA).
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.
Nordion Inc., a leading provider of products and services for the prevention, diagnosis and treatment of disease, today announced an additional randomized, multi-centre Phase III clinical trial for TheraSphere, Nordion's yttrium-90 (Y-90) glass microsphere treatment for liver cancer.
Spectrum Pharmaceuticals and Allos Therapeutics, Inc. today announced that they have signed a definitive agreement under which Spectrum will acquire all of the outstanding shares of Allos for $1.82 per share in cash plus one Contingent Value Right.
Nordion Inc., a leading provider of products and services for the prevention, diagnosis and treatment of disease, today launched a new custom dose feature in Europe and Canada for TheraSphere, Nordion's Y-90 microsphere treatment for liver cancer.
Nordion Inc., a leading provider of products and services to the global health science market, today celebrated the first anniversary of the market introduction of TheraSphere, an innovative radioembolic liver cancer therapy, in the Republic of Turkey.
'SARAH' - a French national collaborative randomized controlled trial of radioembolization with yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma is now open for recruitment
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) on November 18, 2011 to remove the pre-treatment biodistribution evaluation requirement using Indium-111 ZEVALIN imaging dose followed by a gamma scan before administering the ZEVALIN therapeutic dose.
Finding innovative, minimally invasive ways to treat liver cancer-and being able to tailor that treatment individually to patients-are hallmarks of interventional radiologists. Advances in yttrium-90 (Y-90) radioembolization for liver cancer, a leading cause of cancer deaths worldwide, are reported in studies in the October Journal of Vascular and Interventional Radiology.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that various studies on ZEVALIN for Injection were presented at the 11th International Conference on Malignant Lymphoma (ICML), held June 15-18, 2011, in Lugano, Switzerland.
Nordion Inc., a leading provider of products and services to the global health science market, today announced that Theorem Clinical Research, previously Omnicare Clinical Research, a full service Contract Research Organization has been awarded the contract to conduct Nordion's recently announced TheraSphere Phase III clinical trials for the treatment of primary and metastatic liver cancers - STOP-HCC and EPOCH.
In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate.
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, embolization particles will show the most significant growth, both in procedure volume and in revenue, among all devices in the transcatheter embolization and occlusion (TEO) market. Radioembolization is expected to grow from $50 million in sales in 2011 to $128 million in 2015, while drug-eluting beads will grow from $11 million to $28 million over the same period.
Cancer Centers of North Carolina (CCNC), an affiliate of the United Network of US Oncology and the first practice to offer community-based outpatient cancer care in the Triangle with locations in Raleigh, North Raleigh, Cary, Dunn and Clayton, has purchased Wake Radiology Oncology Services (WROS) from Wake Radiology, the oldest and largest multi-site radiology group in central North Carolina.
Interventional radiologists have been the leaders in the use of intra-arterial yttrium-90 radioembolization, since its introduction in 2000, to treat liver cancer.
Nordion Inc., a leading provider of products and services to the global health science market, today shared results from the first multi-site, Phase II clinical trial to evaluate TheraSphere® for treatment of metastatic liver cancer.